Published in Blood on May 15, 2008
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2009) 4.03
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell (2013) 2.22
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet (2009) 1.75
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol (2011) 1.44
Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood (2015) 1.39
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife (2013) 1.36
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia (2013) 1.33
MicroRNA function in myeloid biology. Blood (2011) 1.30
Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci U S A (2010) 1.25
Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood (2010) 1.21
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood (2011) 1.18
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene (2012) 1.16
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood (2012) 1.14
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood (2013) 1.12
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica (2009) 1.11
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica (2013) 1.05
Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med (2009) 1.03
Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol (2009) 0.99
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia (2013) 0.96
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol (2012) 0.93
Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure. Haematologica (2009) 0.93
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia (2014) 0.91
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nat Commun (2016) 0.90
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res (2014) 0.90
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2014) 0.89
Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood (2012) 0.88
Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms. Rev Bras Hematol Hemoter (2011) 0.87
Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res (2010) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget (2010) 0.85
Establishment of a xenograft model of human myelodysplastic syndromes. Haematologica (2010) 0.84
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One (2014) 0.83
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis. Int J Lab Hematol (2009) 0.82
Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study. Haematologica (2009) 0.82
Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. PLoS One (2016) 0.82
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica (2009) 0.81
Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin Dev Immunol (2013) 0.81
Large-vessel thrombosis in intestinal Behçet's disease complicated with myelodysplastic syndrome and trisomy 8. World J Gastroenterol (2012) 0.81
Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma (2015) 0.80
Pathogenic microRNA's in myeloid malignancies. Front Genet (2014) 0.80
L3MBTL1 deficiency directs the differentiation of human embryonic stem cells toward trophectoderm. Stem Cells Dev (2011) 0.80
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances. Cancer Biol Med (2012) 0.80
Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One (2014) 0.79
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer (2012) 0.79
5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. J Biol Chem (2011) 0.79
Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2. Am J Transl Res (2015) 0.78
Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes. Biomed Res Int (2014) 0.78
Histone methylation in myelodysplastic syndromes. Epigenomics (2011) 0.77
The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes. Int J Mol Sci (2016) 0.77
Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. PLoS One (2014) 0.76
Deconstructing innate immune signaling in myelodysplastic syndromes. Exp Hematol (2015) 0.76
The next new target in leukemia: The embryonic stem cell gene SALL4. Mol Cell Oncol (2015) 0.76
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep (2016) 0.76
SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis. Int J Mol Med (2014) 0.76
Loss of p300 accelerates MDS-associated leukemogenesis. Leukemia (2016) 0.75
Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. Biomed Res Int (2014) 0.75
Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion. Exp Ther Med (2013) 0.75
The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores. J Med Life (2014) 0.75
Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience. Yonsei Med J (2016) 0.75
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat Immunol (2016) 0.75
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget (2016) 0.75
Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. Oncol Lett (2015) 0.75
An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614). Clin Pharmacol (2015) 0.75
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report. Mol Clin Oncol (2016) 0.75
[Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification]. Pathologe (2013) 0.75
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia (2017) 0.75